Tokyo, Jan. 21 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000056739) titled 'Introduction of Novel Liquid Biopsy in Genomic Medicine' on Jan. 20.
Study Type:
Observational
Primary Sponsor:
Institute - Seta Clinic Tokyo
Condition:
Condition - Malignant tumor
Healthy person
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - Operational evaluation of two types of liquid biopsy offered by GC genome
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - ･Patients or healthy persons visiting Seta Clinic Tokyo who wish to undergo "DNA CT" or "ai-CANCERCH" testing.
･Patients or healthy persons who, after having been fully informed of the study and with sufficient understanding, have given their free and voluntary written consent to participate in the study.
Key exclusion criteria - ･Patients or healthy persons who are judged to be inappropriate as test subjects by the Principal Investigator or Research Assistants.
Target Size - 10
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2024 Year 09 Month 25 Day
Date of IRB - 2024 Year 10 Month 01 Day
Anticipated trial start date - 2024 Year 10 Month 01 Day
Last follow-up date - 2025 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064789
Disclaimer: Curated by HT Syndication.
